| 68291-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• CAS: 68291-98-5
• 化学式: C8H8N2NaO3S
• 分子量: 235.22
• InChiKey: CXGPJFFXNNHUAY-UHFFFAOYSA-N

物化性质

• 溶解度：
  在水中的溶解度>5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  0.24
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22

制备方法与用途

生物活性方面，Zonisamide sodium（AD 810 sodium）是锌酶碳酸酐酶的抑制剂，对人类线粒体同工酶 hCA II 和 hCA V 的 Ki 值分别为 35.2 nM 和 20.6 nM。该化合物具有抗癫痫活性，并可用于癫痫、癫痫发作和帕金森病的研究。

靶点：

• Ki: 35.2 μM (hCA II), 20.6 nM (hCA V)

文献信息

• Method of treating tremors
  申请人：——

  公开号：US20040142992A1

  公开（公告）日：2004-07-22

  The present invention is directed to a method of treating action tremor or severe essential tremor. Action tremor includes essential tremor, postural tremor, drug-induced or toxic tremor, primary orthostatic tremor, dystonic tremor, neuropathic tremor, and cerebellar tremor. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of zonisamide, or a pharmaceutically acceptable salt thereof. The methods of the present invention are useful in reducing symptoms of tremor. The compounds of the present method can also be used in conjunction with other therapeutic agents commonly used to treat tremor thus enhancing the therapeutic effect of treating tremor.

  本发明涉及一种治疗作用性震颤或严重本质性震颤的方法。震颤包括本质性震颤、姿势性震颤、药物诱发或毒性震颤、原发性正位震颤、肌张力震颤、神经性震颤和小脑震颤。该方法包括向受试者施用药物组合物，其中包含有效量的唑尼沙胺或其药学上可接受的盐。本发明的方法有助于减轻震颤症状。本方法的化合物还可与其他常用于治疗震颤的治疗剂联合使用，从而增强治疗震颤的疗效。
• METHOD OF TREATING TREMORS
  申请人：Eisai Co., Ltd.

  公开号：EP1539145A2

  公开（公告）日：2005-06-15
• DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE
  申请人：Chase Therapeutics Corporation

  公开号：EP3902543A1

  公开（公告）日：2021-11-03
• METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE
  申请人：Tyers Mike

  公开号：US20090076019A1

  公开（公告）日：2009-03-19

  A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.
• ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：CHASE THERAPEUTICS CORPORATION

  公开号：US20210393595A1

  公开（公告）日：2021-12-23

  The present invention provides a combination of a 5HT3-antagonist and/or a NK-1 antagonist with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, zonisamide or a pharmaceutically acceptable salt or solvate thereof, or a statin or a pharmaceutically acceptable salt or solvate thereof, for use for treating a protein misfolding neurodegenerative disease such as Alzheimer's disease, Lewy body disease, Parkinson's disease, or Huntington's disease.